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Abstract
Background: Recent reviews claiming smokeless tobacco increases pancreatic cancer risk appear
not to have considered all available epidemiological evidence; nor were meta-analyses included. We
present a systematic review of studies from North America and Europe, since data are lacking from
other continents. Risk is also difficult to quantify elsewhere due to the various products,
compositions and usage practices involved.
Methods: Epidemiological studies were identified that related pancreatic cancer to use of snuff,
chewing tobacco or unspecified smokeless tobacco. Study details and effect estimates (relative risks
or odds ratios) were extracted, and combined by meta-analyses.
Results: Nine North American and two Scandinavian studies were identified. Reporting was
limited in four studies, so only seven were included in meta-analyses, some providing results for
never smokers, some for the overall population of smokers and non-smokers, and some for both.
Giving preference to study-specific estimates for the overall population, if available, and for never
smokers otherwise, the random-effects estimate for ever smokeless tobacco use was 1.03 (95%
confidence interval 0.71–1.49) based on heterogeneous estimates from seven studies. The estimate
varied little by continent, study type, or type of smokeless tobacco.
Giving preference to estimates for never smokers, if available, and overall population estimates
otherwise, the estimate was 1.14 (0.67–1.93), again based on heterogeneous estimates. Estimates
varied (p = 0.014) between cohort studies (1.75, 1.20–2.54) and case-control studies (0.84, 0.36–
1.97). The value for cohort studies derived mainly from one study, which reported an increase for
never smokers (2.0, 1.2–3.3), but not overall (0.9, 0.7–1.2). This study also contributed to increases
seen for snuff use and for European studies, significant only in fixed-effect analyses.
The studies have various weaknesses, including few exposed cases, reliance in cohort studies on
exposure recorded at baseline, poor control groups in some case-control studies, and lack of a
dose-response. Publication bias, with some negative studies not being presented, is also possible.
Conclusion: At most, the data suggest a possible effect of smokeless tobacco on pancreatic cancer
risk. More evidence is needed. If any risk exists, it is highly likely to be less than that from smoking.
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Background
Smokeless tobacco (ST) is mainly used orally, chewing
tobacco and snuff being the major products used in North
America and Europe. There are several types of chewing
tobacco and snuff, differing in their formulation and in
how the tobacco is treated and used [1-3]. In the United
States, where finely-cut moist snuff or chewing tobacco is
held by users in the gingival buccal area, ST has been an
important part of total tobacco consumption for many
years. For example, in 2000, ST formed 12.9% of tobacco
consumption by weight [4,5], and was used by 4.5% of
men and 0.3% of women [6]. Previously, sales of chewing
tobacco considerably exceeded those of snuff, but since
the 1980s sales of snuff have risen sharply, now exceeding
those of chewing tobacco [4,5]. In Sweden, the only other
economically developed country where ST forms a major
part of tobacco sales (e.g. 53% in 2000), snuff ('snus') is
generally placed between the gum and upper lip [2]. The
Swedish population has a long history of use of snus, sales
of chewing tobacco there being negligible. ST also forms a
few per cent of the market in Canada and in other Scandi-
navian countries [4,5]. ST is also widely used in parts of
Central and South-East Asia. Use occurs in various ways,
with the tobacco used alone or in combination with other
products, such as betel nut quid, slaked lime, areca nut
and even snail shells [1,3,7].
In 2008, a report from the European Community Scien-
tific Committee on Emerging and Newly Identified Health
Risks (SCENIHR) on the health effects of ST [8] noted that
"All STP [ST products] contain nicotine, a potent addictive
substance. They also contain carcinogenic tobacco-spe-
cific nitrosamines, albeit at differing levels. STP are carci-
nogenic to humans and the pancreas has been identified
as a main target organ." The conclusion relating to the
pancreas derived from a review of evidence from eight
studies [9-16], and was identical to that in a draft report
published in 2007 [17]. No meta-analyses were presented,
but it was noted that the pancreas was identified as a main
target organ in two Scandinavian studies. When detailing
the results for these studies, the data cited were not com-
plete. Notably, for the Norway Cohorts Study by Boffetta
et al [10], reference was made to a relative risk [RR] for
ever use of snuff of 1.67 (95% confidence interval [CI]
1.12–2.50), which was based on results for smokers and
non-smokers combined with adjustment for smoking,
with no mention made of the RR of 0.85 (95% CI 0.24–
3.07) specifically for never smokers. In contrast, for the
study of Swedish construction workers by Luo et al [11],
reference was made to a RR of 2.00 (1.20–3.30) specifi-
cally for never smokers, with no reference made to a RR of
0.90 (0.70–1.20), based on results for smokers and non-
smokers combined, with adjustment for smoking.
The previous year, in 2007, the International Agency of
Research on Cancer (IARC) published a monograph enti-
tled "smokeless tobacco and some tobacco-specific nitro-
samines" [2], an earlier indication of its findings having
been made available three years before this [18]. The
monograph concluded that "there is sufficient evidence
in humans for the carcinogenicity of smokeless tobacco.
Smokeless tobacco causes cancers of the oral cavity and
pancreas." The monograph considered the same studies as
had SCENIHR [8], but did not consider the Swedish Con-
struction Workers Study [11] and one other study [15]
published in 2007, after the IARC working group had
completed their deliberations. As in the SCENIHR report,
the IARC report did not mention the lack of association of
snuff with risk in never smokers in the Norway Cohorts
Study [10].
Given the lack of meta-analyses in either report, the appar-
ent failure to consider all the relevant data, and the exist-
ence of other studies providing a certain amount of
additional information [19-21], we decided to carry out a
detailed review of all the available evidence relating ST use
to pancreatic cancer in North America and Europe. As in
some other reviews of possible effects of ST use (e.g. [22-
26], results from other areas (such as South East India),
where ST is often mixed with other substances, are not
considered. However, it should be noted that no studies
of ST and pancreatic cancer conducted outside North
America and Europe were referred to in either the IARC
monograph 89 [2] or the SCENIHR report [8].
Methods
Study identification and selection
Relevant studies were identified by literature searches
through December 2007 using EMBASE, MEDLINE and
references listed in the identified publications. The search
was not limited by period or language. The main searches
were based on combinations of the terms "smokeless
tobacco", "chewing tobacco", "snuff", and "snus" for
exposure and "pancreatic cancer" for outcome. Study
selection was restricted to epidemiological reports which
presented data on pancreatic cancer mortality or morbid-
ity associated with use of snuff, chewing tobacco or
unspecified ST.
All reports had to satisfy the following Inclusion criteria:
based on research on humans, of cohort or case-control
design, any form of pancreatic cancer as the outcome, and
chewing tobacco, orally used moist snuff or unspecified
smokeless tobacco as the exposure. The reports also had to
satisfy the Exclusion criteria: sample included in a more
complete or recent study, conducted in an Asian popula-
tion, no control group or inappropriate design (case
report, qualitative study or review/meta-analysis).
Data extraction
From each study, details were extracted of the study
design, location and timing, and of the potential con-BMC Cancer 2008, 8:356 http://www.biomedcentral.com/1471-2407/8/356
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founding variables considered. Where available, estimates
of the RR or odds ratio [OR] associated with ST use,
including dose-response data, were extracted together
with their associated CI. On occasion, the effect estimates
(RR or OR) were calculated from data provided in the
source publication. Attention was restricted to estimates
where the two ST use groups being compared were both
never smokers, both current smokers, both former smok-
ers, or both the overall population of smokers and non-
smokers combined.
Meta-analyses
Fixed-effect and random-effects meta-analyses were con-
ducted as described by Fleiss and Gross [27] with the out-
put showing the combined effect estimate (with 95% CI)
from each analysis, together with the results of the chis-
quared test of homogeneity and the I2 statistic [28]. For
selected meta-analyses, a forest plot is also shown. Each
estimate is shown as a rectangle, the area of which is pro-
portional to its weight. The CI is indicated by a horizontal
line. The data are plotted on a logarithmic scale so that the
estimate is centred within the CI. Also shown in the plot
are the actual values of the estimate and its CI and weight.
Results from a random effects meta-analysis are also
shown. The combined estimate is presented as a diamond
with the width corresponding to the CI, and the estimate
as the centre of the diamond.
As will become apparent later, data in a form suitable for
meta-analyses were only available for seven studies, with
some only reporting results for never smokers and some
only reporting results for the overall population of smok-
ers and non-smokers combined, and some both. Accord-
ingly, two major sets of estimates were selected for meta-
analysis. One was based on overall population estimates
where available, otherwise on estimates for never smok-
ers. The other was based on the never smoker estimates
where available, otherwise on estimates for the overall
population. For each set, preference was given to esti-
mates comparing ever ST use with never ST use, as these
were always available, while alternatives (e.g. comparing
current and never ST use) rarely were. Where separate esti-
mates were available for chewing tobacco and for snuff,
results for chewing tobacco were used in the main meta-
analyses, though alternative analyses preferring estimates
for snuff were also carried out. Meta-analyses were also
conducted for subdivisions of the studies by continent,
type of ST, study type (prospective or case-control) and
smoking group.
Results
Table 1 summarizes details of the four cohort studies [9-
11,19] for which results have been reported relating ST
use to pancreatic cancer incidence or mortality. The
sources cited give the most recent (and comprehensive)
publications, although for two of these studies earlier
publications [29-32] provide more limited results from a
shorter follow-up. The studies are all in males, except for
a very small proportion of females in the US veterans
study [33]. Two of the studies were conducted in the USA
and concern unspecified ST. The other two were con-
ducted in Scandinavia and concern snuff use. The largest
study, of US veterans, has only provided limited results,
for fifteen years of follow-up, in an abstract [19]. The
other three studies involve follow-up periods of 20 to 36
years. All of the cohort studies use exposure data as
recorded at baseline.
Table 2 summarizes details of seven case-control studies
[12-16,20,21], all conducted in the USA or Canada.
Results for ST are available for males and females com-
bined in four studies [14,15,20,21] and for males only in
the other three studies [12,13,16]. The studies vary as to
whether they report results for chewing tobacco and snuff
separately [13,15,20], for chewing tobacco only [12,21],
or for combined ST use based on chewing tobacco or snuff
[14,16]. Of the seven studies, all concern incident cancer,
except for one [21] that makes no such distinction. In
humans, the great majority of pancreatic cancers are exo-
crine adenocarcinomas, endocrine (islet-cell) carcinomas
being far less common, so that the stated restrictions to
"carcinoma of the exocrine pancreas" in one study [14] or
to "pancreatic adenocarcinoma" in another [15] should
be of little consequence. One study also included cancers
of the bile duct or gall bladder [21], but these form only a
small proportion of the total. Three studies used popula-
tion based controls [12,14,21], while two used hospital
patients [13,20] and one hospital visitors [15]. One study
[16] was based on the Third National Cancer Survey and
compared pancreatic cancer cases with cancers considered
not to be associated with smoking. One study [12] used
only surrogate respondents, while two studies [20,21]
used some. The numbers of cases studied varied from 113
[16] to 808 [15].
Effect estimates
Table 3 summarizes the results from the 11 studies. For
four of the studies [12,19-21], RRs with CIs were not avail-
able, so the studies could not be included in the meta-
analyses. Of those four studies, the Louisiana [20], Wash-
ington State [12] and Quebec [21] studies reported no
indication of an increased risk of pancreatic cancer associ-
ated with ST use, but the US Veterans Study [19] did indi-
cate an elevated RR of 1.65, although the abstract made no
statement about significance. Of the other seven studies,
the Norway cohorts [10] and Swedish construction work-
ers [11] studies reported a significant excess in some anal-
yses but not others, while the Nine Hospital Study [13]
reported a near significant increase in one analysis. The
Third National Cancer Survey [16] reported a decreaseBMC Cancer 2008, 8:356 http://www.biomedcentral.com/1471-2407/8/356
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that we estimate as significant. The other three studies
[9,14,15] reported no significant increase or decrease.
Table 4 presents the results of the meta-analyses using
overall population estimates where available, and esti-
mates for never smokers if not. All the overall population
estimates were adjusted for smoking. The principal analy-
sis (see also Figure 1), based on RR/OR estimates num-
bered 2, 3, 9, 13, 19, 20 and 21 in Table 3, shows no
evidence of an effect of ST use, since both the fixed-effect
estimate (1.04, 95% CI 0.86–1.25) and the random-
effects estimate (1.03, 0.71–1.49), were only slightly in
excess of 1.00 and not statistically significant. However,
there is evidence of heterogeneity (chisquared 15.95 on 6
d.f., p = 0.014). The lack of a statistically significant asso-
ciation is unaffected by using estimates for snuff rather
than chewing tobacco in the two studies [13,15] where
there was a choice.
The significant heterogeneity of the seven study-specific
estimates cannot readily be explained. Estimates do not
vary significantly by continent and are similar for chewing
tobacco, snuff and unspecified ST. Excluding results for
never smokers had little effect on the estimates. Although
estimates were significantly (p = 0.034) higher for cohort
studies than for case-control studies, heterogeneity was
still evident in the cohort studies, and indeed in all of the
analyses shown in Table 4 except for the case-control stud-
ies. No single study contributes notably to the heterogene-
ity. Excluding the Third National Cancer Survey Study
[16], which used a design that may be inappropriate (see
discussion), and unusually reported a significant reduc-
tion in risk associated with ST use, still leaves the overall
estimate not significantly different from 1.00 and reduces
the heterogeneity only slightly.
Table 5 presents the results of the meta-analyses using esti-
mates for never smokers where available, and overall pop-
ulation estimates if not. Generally, these analyses are
more suggestive of a possible effect than the results shown
in Table 4. For the principal analysis (see also Figure 2),
based on estimates 2, 6, 10, 13, 18, 20 and 23, the fixed-
Table 1: Cohort studies of smokeless tobacco and pancreatic cancer
Study details US Veterans Study Lutheran Brotherhood Study Norway Cohorts Study Swedish Construction 
Workers Study
Sourcea Winn et al [19]b Zheng et al [9]c Boffetta et al [10]d Luo et al [11]
Country USA USA Norway Sweden
Population US veterans insurance 
policyholders
Lutheran brotherhood 
insurance policyholderse
General population samples and 
relatives of Norwegian migrants 
to the USA
Construction workers
Baseline survey 1954 1966 1964, 1967 1978–1992
Sex > 99.5% Male Male Male Male
Follow-up 1954–1969 1966–1986 1966–2001 1978–2004
Sample sizef Approx 300,000 17,633 10,136 279,897
Endpoint Mortality Mortality Incidenceg Incidence
Data on ST use ST unspecified ST unspecified Snuff Snuff
Adjustment factorsh Age Age, smoking, alcohol Age, smoking Age, smoking, body mass 
index
a The source given is for the latest follow-up
b The source is an abstract. Some of the study information about the US Veterans Study was obtained from other sources [33]
c Page 103 of IARC Monograph 37 [30] summarizes 15 year follow-up results from this study based on two abstracts [29,32]
d 11 year follow-up results from this study are reported on page 103 of IARC Monograph 37 [30] based on two abstracts [29,32], while 14 year 
follow-up results are given by Heuch et al [31]
e White
f Numbers used in specific analyses may be less than this
g Cases diagnosed on the basis of a clinical examination or death certificate only were excluded
h Adjustment factors used in analysisBMC Cancer 2008, 8:356 http://www.biomedcentral.com/1471-2407/8/356
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Table 2: Case-control studies of smokeless tobacco and pancreatic cancer
Study Details Third National Cancer 
Survey Study
Louisiana Study Washington State Study Quebec Study
Source Williams et al [16] Falk et al [20] Farrow et al[12] Ghadirian et al [21]
Country USAa USA USA Canada
Timing 1969–1971 1979–1983 1982–1986 1984–1988
Sex Malesb Males and females Malesc Males and females
Cases Incident, pancreatic cancer Incident, pancreatic cancer Incident, pancreatic cancer Diagnosed, pancreatic, bile 
duct or gall bladder cancer
Controls Incident, cancers not 
associated with smoking
Hospital, without diet-
altering chronic disease
Population, random-digit 
dialling
Population, random-digit 
dialling
Matching None Age, sex, race Age, area Age, sex, area
Surrogate respondents None > 50% (cases), 13% 
(controls)
100% (cases), 100% (controls) 75% (cases), 17% (controls)
Casesd 113e 363 168 179
Controlsd 2074e 1234 195 239
Data on ST usef Chewing or snuff Chewing, snuff Chewing Chewing
Adjustment factorsg Age, race, smoking Unstated Race, education Age, sex, smoking, 
education, proxy response
Nine Hospital Study Fifteen County Study Texas Study
Source Muscat et al [13] Alguacil and Silverman [14] Hassan et al [15]
Country USAh USAi USA
Timing 1985–1993 1986–1989 2000–2006
Sex Malesb Males and females Males and females
Cases Incident, pancreatic
cancer
Incident, exocrine 
pancreatic cancer
Incident, pancreatic 
adenocarcinoma
Controls Hospital, diseases not 
associated with smoking
Population, random-digit 
diallingj
Hospital visitors, healthy, no 
cancer history
Matching Age, sex, race, hospital, 
year of diagnosis
Age, sex, race Age, sex, race
Surrogate respondents None None NoneBMC Cancer 2008, 8:356 http://www.biomedcentral.com/1471-2407/8/356
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effect estimate is near significant (1.32, 95% CI 0.98–
1.77). However there is substantial heterogeneity between
studies (chisquared 16.06 on 6 d.f., p = 0.013), and the
random-effects estimate is lower and not significant (1.14,
0.67–1.93). There is no real indication of an effect of ST in
case-control studies, in studies in North America, or in
studies of chewing tobacco or unspecified ST use, though
again estimates were heterogeneous. There is, however,
more indication of an effect in cohort studies, in studies
in Sweden or Norway, and in studies of snuff, where fixed-
effect estimates of the RR associated with ST exposure are
all significant or borderline significant (cohort 1.75 95%
CI 1.20–2.54, Sweden or Norway 1.78, 1.11–2.85, and
snuff 1.54, 1.00–2.37). All three estimates are strongly
affected by the major contribution of the RR estimate of
2.00 (1.20–3.30) for the Swedish Construction Workers
Study [9], which for reasons noted in the discussion may
substantially overestimate any true relationship. This
study contributes 54.7% of the weight for cohort studies,
86.4% of the weight for studies in Sweden and Norway,
and 72.6% of the weight for studies of snuff. Though none
of these three analyses themselves shows significant heter-
ogeneity, the marked heterogeneity for the "all studies"
meta-analysis in Table 5 suggests that random-effects esti-
mates may possibly be more appropriate. If so, only the
estimate for cohort studies remains significant. This com-
bined estimate of 1.75 (1.20–2.54) is based on three indi-
vidual study estimates, that noted above from the Swedish
Construction Workers Study [11] of 2.00 (95% CI 1.20–
3.30, weight 15.02), an estimate of 0.85 (0.24–3.07, 2.37)
from the Norway Cohort Study [10] and an estimate of
1.70 (0.90–3.10, 10.05) from the Lutheran Brotherhood
Study [9], this final estimate not being specifically for
never smokers. A significant fixed-effect estimate (1.46,
1.08–1.99) is also seen when the Third National Cancer
Survey Study [16] is excluded from consideration on the
grounds of its study design. However the random-effects
estimate is not significant, and again the Swedish Con-
struction Workers Study [11] contributes substantially
(37.1% of the weight) to the analysis.
The two Scandinavian studies [10,11] reported results for
current and former ST use (see Table 3). In both studies
the risk estimate for quitters is similar to that for continu-
ing users.
Table 6 shows the limited data available on a possible
dose relationship between ST use and risk of pancreatic
cancer. The three studies [11,15,16] each provide quite
similar risk estimates for high and low usage, albeit based
on small numbers of exposed cases at each usage level.
Not shown in Table 6 are the dose-response results from
the Fifteen County Study [14], which did report a signifi-
cant trend (p = 0.04) with ounces/week ST ever used
(though not with years used), based on seven ST-exposed
cases. This was based on an analysis that may be biased by
the fact that the exposed group, but not the reference
group, may have smoked pipes and cigars. Therefore, it
did not satisfy our criteria for consideration in analysis. In
any case the trend, based on ORs of 1.00 (reference), 0.30
(95% CI 0.04–2.50) for ≤ 2.5 ounces ST per week, and
3.50 (95% CI 1.10–10.60) for > 2.5 ounces ST per week,
was partly due to a low OR in the low exposure group. It
is clear that the overall data have not demonstrated a
dose-response relationship.
Discussion
When preference is given to overall population smoking-
adjusted estimates of pancreatic cancer risk associated
with ST, on the basis that these provide greater power to
detect a possible association, the meta-analyses (Table 4)
show no clear evidence of any increase in risk associated
Casesd 290e 154 808
Controlsd 572e 844 808
Data on ST usef Chewing, snuff Chewing or snuff Chewing, snuff
Adjustment factorsg None Age, sex, race, site, cigar 
smoking
Age, sex, race, smoking, 
diabetes, alcohol, education, 
area, marital status
a Nationwide
b Females were also studied, but results were only available for males
c Only married men were included
d Numbers used in specific analyses may be less than this
e Numbers are of males
f "Chewing or snuff" implies that results were only available for combined ST use; "chewing, snuff" implies they were separately available
g Adjustment factors used in analysis
h Conducted in four hospitals in New York, two in Philadelphia, and one each in Chicago, and Detroit
i Conducted in two counties in Atlanta, three in Detroit and ten in the state of New Jersey
j Controls aged 65–79 were drawn from Medicare and Medicaid service rosters
Table 2: Case-control studies of smokeless tobacco and pancreatic cancer (Continued)BMC Cancer 2008, 8:356 http://www.biomedcentral.com/1471-2407/8/356
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Table 3: RR/OR of pancreatic cancer associated with smokeless tobacco use
Studya ST use Smoking Sex RR/OR
Typeb Exposurec No. Casesd Estimate (95% CI) Notes
Cohort studies RR
US Veterans [19] ST Use Never M 1 NA 1.65 e, f
Lutheran Brotherhood [9] ST Ever Any M 2 16 1.70(0.90–3.10)
Norway Cohorts [10] Snuff Ever Any M 3 45 1.67(1.12–2.50) g
Former Any 4 18 1.80(1.04–3.09)
Current Any 5 27 1.60(1.00–2.55)
Ever Never 6 3 0.85(0.24–3.07)
Ever Former 7 14 1.37(0.59–3.17)
Ever Current 8 28 1.86(1.13–3.05)
Swedish Construction Workers [11] Snuff Ever Any M 9 NA 0.90(0.70–1.20)
Ever Never 10 20 2.00(1.20–3.30)
Former Never 11 2 1.40(0.40–5.90)
Current Never 12 18 2.10(1.20–3.60)
Case-control studies OR
Third National Cancer Survey [16] ST Ever Any M 13 3 0.29(0.09–0.92) h
Louisiana [20] Chewing Use Any M+F 14 NA "No excess risk"
Snuff Use Any 15 NA "No excess risk"
Washington State [12] Chewing Ever Any M 16 NA 0.80 (Not sig.) i
Quebec [21] Chewing Use Any M+F 17 NA "Not associated with increased risk"
Nine Hospital [13] Chewing Ever Neverj M 18 6 2.82(0.95–9.39) k
Snuff Ever Any 19 2 1.32(0.22–7.93) h
Fifteen County [14] ST Ever Never M+F 20 5 1.10(0.40–3.10) l
Texas [15] Chewing Ever Any M+F 21 34 0.70(0.40–1.10)
Ever Ever 22 24 0.70(0.40–1.20)
Ever Never 23 10 0.60(0.30–1.40)
Snuff Ever Any 24 18 0.60(0.30–1.10)BMC Cancer 2008, 8:356 http://www.biomedcentral.com/1471-2407/8/356
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with ST use. In contrast, when preference is given to risk
estimates for never smokers, on the basis that these avoid
possible confounding by smoking, the meta-analyses
(Table 5) show more indication of an increase in risk.
While no increased risk is demonstrated in studies in
North America or in case-control studies (all of which
Ever Ever 25 14 0.70(0.30–1.40)
Ever Never 26 4 0.50(0.10–1.50)
a Fuller details of the studies are given in Tables 1 and 2
b ST implies smokeless tobacco unspecified or combined snuff use or chewing
c Ever, former and current ST are compared with never ST. Use indicates timing not given and comparison is with non use
d Cases in ST users as defined, NA = not available
e The abstract suggests the results are for never smokers, but this is not totally clear. The population included < 0.5% females. In earlier reports 
from this study [30] RRs were reported of 3.3 (statistically significant) for former ST users, and of 2.1 (not significant) for current ST users, based 
on, respectively, 7 and 5 cases in the exposed group
f Confidence intervals could not be calculated
g In earlier reports the risk of histologically-reported pancreatic cancer in regular ST users was stated to be 2.2 ("significant") [30] and 2.9 (trend p 
= 0.06) [31]
h Estimated from data provided
i Additional adjustment for age and dietary factors did not materially affect the odds ratios
j Includes long term (> 10) years quitters
k Personal communication from the author
l The authors also reported an adjusted OR of 1.4 (0.5–3.6) for the comparison (among never cigarette smokers) of ever used ST, but may have 
used pipe or cigar versus never used ST, pipe or cigar
Table 3: RR/OR of pancreatic cancer associated with smokeless tobacco use (Continued)
Forest plot of study-specific effect estimates and 95% CIs, using overall population estimates where available Figure 1
Forest plot of study-specific effect estimates and 95% CIs, using overall population estimates where available.BMC Cancer 2008, 8:356 http://www.biomedcentral.com/1471-2407/8/356
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were in North America), there is some evidence of an
increased risk in studies in Sweden or Norway and in the
cohort studies. This is also suggested by an analysis
excluding the unusually low estimate from the Third
National Cancer Survey [16], a study which in any case
suffers from a weakness we describe later.
Of the three cohort studies contributing to the analysis in
Table 5, one conducted in the USA, one in Sweden and
one in Norway, the Norway Cohorts Study [10] shows no
increase at all (RR 0.85, 95% CI 0.24–3.07) in never
smokers, but the estimate is based on only three pancre-
atic cancer cases in snuff users, while the Lutheran Broth-
erhood Study [9] shows a non-significant increase (1.70,
0.90–3.10) based on 16 cases in ST users in an analysis for
smokers and non-smokers combined adjusted for smok-
ing (and also age and alcohol).
The major contributor to the observed increase derives
from the recently reported Swedish Construction Workers
Study [11], where the RR was 2.00 (1.20–3.30), based on
20 cases of pancreatic cancer in snuff-using never smok-
ers. In considering this report by Luo et al, a number of
points should be made.
First, the study was based on follow-up until the end of
2004, based on exposure information obtained at the first
health check-up of those cohort members with at least
one visit in the 1978–1992 period. The authors reported
that a proportion of subjects classified on their first visit as
never smoking were recorded in a later visit as having
smoked, and that this proportion was greater in subjects
who initially reported use of snus (12% vs 7%). They
stated (based on an analysis not reported in detail) that
bias due to this misclassification would have had little
effect on the risk estimates. However, the estimated bias
may have been greater, had account been taken of the pos-
sibility of subjects taking up smoking later in the follow-
up period, when data were not collected.
Second, as pointed out by Rodu [34], the authors
excluded workers enrolled in their cohort from 1971 to
Table 4: Meta-analyses of overall population estimates of pancreatic cancer risk associated with ST, using estimates for never smokers 
if overall population estimates are not availablea
Meta-analysis Estimates Included Fixed-effect RR (95% CI) Random-effects RR (95% CI) Heterogeneity
Chisquared (d.f.) I2 p
All studies 2,3,9,13,19,20,21 1.04(0.86–1.25) 1.03(0.71–1.49) 15.95 (6) 62.4 0.014
All, preferring snuff to chewingb 2,3,9,13,19,20,24 1.04(0.86–1.27) 1.01(0.68–1.50) 16.35 (6) 63.3 0.012
USA or Canada 2,13,19,20,21 0.92(0.65–1.29) 0.89(0.50–1.60) 8.97 (4) 55.4 0.062
Sweden or Norwayc 3,9 1.09(0.87–1.36) 1.20(0.66–2.20) 6.28 (1) 84.1 0.012
Cohort 2,3,9 1.15(0.93–1.42) 1.31(0.82–2.11) 8.03 (2) 75.1 0.018
Case-controld 13,19,20,21 0.70(0.46–1.05) 0.70(0.43–1.13) 3.44 (3) 12.7 0.329
Chewing tobacco 18,21 0.88(0.55–1.40) 1.27(0.33–4.92) 4.76 (1) 79.0 0.029
Snuff 3,9,19,24 1.03(0.83–1.27) 1.02(0.64–1.64) 9.26 (2) 67.6 0.026
ST unspecified 2,13,20 1.14 (0.70–1.84) 0.89(0.33–2.40) 6.94 (2) 71.2 0.031
Overall estimates exclusively 2,3,9,13,19,21 1.03(0.85–1.25) 1.01(0.67–1.54) 15.93 (5) 68.6 0.007
Excluding Third National Cancer 
Survey Study[16]
2,3,9,19,20,21 1.07(0.89–1.29) 1.13(0.80–1.59) 11.22 (5) 55.4 0.047
a See Table 3 for the individual study estimates
b Where estimates for both snuff and chewing are available
c There was no significant variation by continent (chisquared = 0.70 on 1 d.f., p = 0.404)
d There was significant variation by study type (chisquared = 4.48 on 1 d.f., p = 0.034)BMC Cancer 2008, 8:356 http://www.biomedcentral.com/1471-2407/8/356
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1975 because of "ambiguities" in questionnaire coding,
despite an earlier report on snus and cardiovascular dis-
ease from this cohort [35] being based only on workers
enrolled in the years excluded by Luo et al (1971 to 1974).
Finally, the study provided no indication of an increase in
the overall population of smokers and non-smokers com-
bined, with the RR adjusted for age, smoking and body
mass index estimated as 0.90 (95% CI 0.70–1.20).
Though this estimate would have been based on consider-
ably more snuff-using pancreatic cancer cases, Luo et al
tended to dismiss this finding, and placed far more reli-
ance on the estimate for never smokers, as this avoids
residual confounding by smoking. They noted that "previ-
ous evidence, reinforced by observed data in the present
study (not shown), suggests that individuals who com-
bine smoking with snus use smoke less and might
increase their overall chances of subsequent abstinence,
compared with those who only smoke". While some bias
may be present for this reason, it seems implausible that
it could possibly explain the huge difference between the
estimates for ever vs. never snuff use of 0.90 (0.70–1.20)
for smokers and non-smokers combined and that of 2.00
(1.20–3.30) for never smokers. The same publication [11]
also reports corresponding results for lung cancer of 0.70
(0.60–0.70) for smokers and non-smokers combined and
of 0.80 (0.50–1.30) for never smokers. Given that smok-
ing has a much greater effect on lung cancer risk than on
pancreatic cancer risk [36,37], any residual confounding
in the estimated ever vs. never snuff use for smokers and
non-smokers combined should be substantially greater
for lung cancer than for pancreatic cancer. The lack of any
marked difference between the two estimates for lung can-
cer suggests residual confounding cannot explain more
than a minor part of the difference between the two esti-
mates for pancreas cancer. The high estimate in snuff users
for never smokers in the Swedish Construction Workers
Study seems therefore likely to be due to other reasons,
including possibly chance.
No epidemiological study is perfect, and there are weak-
nesses in those studies that showed no evidence of an associ-
Table 5: Meta-analyses of estimates of pancreatic cancer risk associated with ST for never smokers, using overall population estimates 
if never smoker estimates are not availablea
Meta-analysis Estimates
Included
Fixed-effect
RR (85% CI)
Random-effects
RR (95% CI)
Heterogeneity
Chisquared (d.f.) I2 P
All studies 2,6,10,13,18,20,23 1.32(0.98–1.77) 1.14(0.67–1.93) 16.06 (6) 62.6 0.013
All preferring snuff to chewingb 2,6,10,13,19,20,26 1.35(0.98–1.86) 1.08(0.64–1.82) 12.31 (6) 51.2 0.055
USA or Canada 2,13,18,20,23 1.08(0.73–1.58) 1.00(0.50–2.02) 11.92 (4) 66.4 0.018
Sweden or Norwayc 6,10 1.78(1.11–2.85) 1.61(0.77–3.34) 1.50 (1) 33.2 0.221
Cohort 2,6,10 1.75 (1.20–2.54) 1.75(1.20–2.54) 1.51 (2) 0.0 0.470
Case-controld 13,18,20,23 0.81(0.49–1.32) 0.84(0.36–1.97) 8.48 (3) 64.6 0.037
Chewing tobacco 18,23 0.97(0.51–1.84) 1.22(0.27–5.55) 4.83 (1) 79.3 0.028
Snuff 6,10,19,26 1.54(1.00–2.37) 1.25(0.64–2.44) 4.54 (3) 33.9 0.209
ST unspecified 2,13,20 1.14(0.70–1.84) 0.89(0.33–2.40) 6.94 (2) 71.2 0.031
Never smoking exclusively 6,10,18,20,23 1.39(0.98–1.99) 1.28(0.71–2.30) 8.80 (4) 54.5 0.066
Excluding Third National Cancer Survey Study [16] 2,6,10,18,20,23 1.46(1.08–1.99) 1.38(0.88–2.15) 9.10 (5) 45.0 0.105
a See Table 3 for the individual study estimates
b Where estimates for both snuff and chewing are available
c There was no significant variation by continent (chisquared = 2.64 on 1 d.f., p = 0.104)
d There was significant variation by study type (chisquared = 6.07 on 1 d.f., p = 0.014)BMC Cancer 2008, 8:356 http://www.biomedcentral.com/1471-2407/8/356
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ation of ST use with pancreatic cancer (see below). However,
given the reliance that has been placed on the Swedish Con-
struction Workers Study in a recent review ([8]), it is not
inappropriate to have focused on some particular weak-
nesses of this study, as well as to have pointed out that esti-
mates for other comparisons in this study do not show an
association of ST with increased pancreatic cancer risk.
Considering the evidence as a whole, there are a number
of limitations which should be pointed out. These include
the small number of exposed cases, with the main analysis
for never smokers based on a total of only 63 exposed
cases from the seven studies providing data, limited con-
trol of confounding with, for example, no study at all hav-
ing taken diet into account (other than alcohol) in their
analyses of risk from ST, and the very limited reporting of
results relating to ST use for a number of the studies, either
because only an abstract was available [19], or because ST
was not a major issue in the publication [9,12,13,15,20].
Individual study weaknesses are also an issue. The Louisi-
ana Study and the Quebec Study [20,21] used surrogate
respondents markedly more often for cases than for con-
trols. The analysis of the Third National Cancer Survey
data [16] included in its control group of cancers not asso-
ciated with smoking some (e.g. kidney cancer, stomach
cancer and leukaemia) for which there is now evidence of
a moderate relationship [37]. The Louisiana Study [20]
used a control group where exclusions were based on
whether the conditions were suspected of altering diet,
rather than on grounds of an association with tobacco
use. Reliance, in the four cohort studies [9-11,19], all
involving follow-up of at least 15 years, on exposure data
recorded at baseline, as already noted for the Swedish
Construction Workers Study [11], is also a problem. In
regard to the Norway Cohorts Study [10], this issue has
also been referred to by Ramström [38], who comments
on the considerable changes in snus use and smoking over
the long follow-up period.
Other general points affecting the overall interpretation
are the lack of evidence of any dose-response relationship,
and possible publication bias, not only due to failure to
publish data that show no effect, but also to failure to
Forest plot of study-specific effect-estimates and 95% CIs, using estimates for never (or non-current) smokers where available Figure 2
Forest plot of study-specific effect-estimates and 95% CIs, using estimates for never (or non-current) smokers 
where available.BMC Cancer 2008, 8:356 http://www.biomedcentral.com/1471-2407/8/356
Page 12 of 14
(page number not for citation purposes)
present data in a form suitable for meta-analysis where no
relationship is seen [12,20,21].
While it remains possible that ST may increase the risk of
pancreatic cancer, more evidence is clearly needed to dem-
onstrate this. In any event, any excess risk is highly likely
to be less than that associated with active smoking, where
there is clear evidence that the risk increases with daily cig-
arette consumption and the number of years of smoking,
and RRs range from three up to five at the highest levels of
smoking [36,37].
Our conclusions are not in line with those of the
SCENIHR report [8] or of IARC Monograph 89 [2]. The
SCENIHR report, as already noted, was limited by empha-
sis on specific results from the Norway Cohorts Study [10]
and from the Swedish Construction Workers Study [11]
without citing other relevant results from these two stud-
ies. IARC Monograph 89 [2] did not include some recent
studies [11,15] and based its conclusions on four studies;
one of these [9] did not report a significant relationship
with ST use, one of these [13] reported a marginally signif-
icant association with chewing tobacco but not snuff, one
of these [14] reported no overall association with ST use,
but a marginally significant trend with amount used in an
analysis that, as explained above, is biased, and one of
these [10] reported an association with snuff use in an
analysis which effectively assumed that such use would
not change over a follow-up period of over 30 years, and
also found no association with snuff use in never smokers.
Both reviews omitted some relevant references [19-21]
and neither included any meta-analyses. Taking into
Table 6: Dose-response data for smokeless tobacco and pancreatic cancer
Studya Smoking Sex ST use RR/OR
Type Exposure Cases Estimate
(95% CI)
Swedish Construction Workers [11] Never M Snuff Never 63 1.00 (reference)
1–9 g/day 6 1.90 (0.80–4.30)
10+ g/day 13 2.10 (1.10–3.80)
Third National Cancer Survey [16] Any M STb Never 88 1.00 (reference)
Lowc 2 0.31 (0.08–1.27)d
Highc 1 0.25 (0.04–1.89)d
Texas [15] Anye M+F Chewing Never 774 1.00 (reference)
Low/moderatef 22 0.60 (0.30–1.20)
High 12 0.60 (0.30–1.20)
Snuff Never 790 1.00 (reference)
Low/moderatef 9 0.60 (0.20–1.50)
Highg 9 0.60 (0.20–1.30)
a Fuller details of the studies are given in Tables 1 and 2
b Chewing or snuff
c The exposed population was divided into approximately equal numbers by the product of consumption x years of use
d CI were estimated from data provided
e The source also provides results for ever cigarette smokers – chewing 1.00, 0.70 (0.40–1.40), 0.50 (0.20–1.50), snuff 1.00, 0.80 (0.30–2.10), 0.50 
(0.20–1.50), and also for never cigarette smokers – chewing 1.00, 0.60 (0.20–2.30), 0.60 (0.20–1.70), and snuff 1.00, 0.00, 0.60 (0.20–2.10)
f Low or moderate intake: ≤ 20 time-years (times/day x years of use)
g High intake: > 20 time-yearsBMC Cancer 2008, 8:356 http://www.biomedcentral.com/1471-2407/8/356
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account the limitations of the SCENIHR report [8] and of
IARC Monograph 89 [2], and also the weaknesses of the
available data, we consider that our analysis more accu-
rately reflects the present evidence regarding the risk of
pancreatic cancer associated with smokeless tobacco use,
and indicates that an effect has not been demonstrated.
Conclusion
The available data relating pancreatic cancer to ST use are
limited, and relatively weak. Random-effects meta-analy-
ses based on evidence from seven studies do not show a
significant relationship of ST use with pancreatic risk,
whether (a) attention is restricted specifically to estimates
for never smokers (RR 1.28, 95% CI 0.71–2.30, n = 5), (b)
estimates for never smokers are used where available and
overall population estimates used otherwise (1.14, 0.67–
1.93, n = 7), or (c) overall population estimates are used
where there is a choice (1.03, 0.71–1.49, n = 7). While
some subgroup analyses based on the second set of esti-
mates seem to suggest a possible association, all of these
are heavily dependent on the contribution of one specific
relative risk estimate from one study with known weak-
nesses [11].
The data, taken as a whole, are no more than suggestive of
a possible effect. More evidence is needed to determine if
a true relationship exists. Any risk that may exist is highly
likely to be less than that associated with active smoking.
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